Optimized Therapeutic (177)Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer

Clinical trials have shown the significant efficacy of [(177)Lu]Lu-PSMA-617 for treating prostate cancer. However, the pharmacokinetic characteristics and therapeutic performance of [(177)Lu]Lu-PSMA-617 still need further improvement to meet clinical expectations. The aim of this study was to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yitian, Zhang, Xiaojun, Duan, Xiaojiang, Yang, Xing, Wang, Feng, Zhang, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782218/
https://www.ncbi.nlm.nih.gov/pubmed/36558981
http://dx.doi.org/10.3390/ph15121530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782218/
https://www.ncbi.nlm.nih.gov/pubmed/36558981
http://dx.doi.org/10.3390/ph15121530

Ejemplares similares